DNA vaccine for use in pancreatic cancer patients
AssigneeVaximm AG
InventorHeinz Lubenau
Life of this patent
Estimating the term…
Abstract
The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
Claims18
A method of providing cancer immunotherapy comprising administering to a patient suffering from a cancer, a DNA vaccine comprising an attenuated mutant strain of Salmonella typhi Ty21a comprising an expression cassette encoding a human VEGFR-2 having the amino acid sequence of SEQ ID NO 1, wherein a single dose of the vaccine is 109 colony forming units (CFU) or less than 109 CFU.
A method of providing cancer immunotherapy to a cancer patient comprising administering to the patient a DNA vaccine VXM01, comprising the attenuated Salmonella typhi strain Ty21a transformed by a 7580 bp plasmid, the plasmid comprising a DNA encoding the VEGFR-2 protein of SEQ ID NO 1 under the control of a CMV promoter, the kanamycin resistance gene, and the pMB1 ori, and is designated as pVAX10.VR2-1, and wherein a single dose of the vaccine is 109 CFU or less than 109 CFU.
Dependencies are inferred from the claim text.